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ABSTRACT
THE EFFECTS OF TRANEXAMIC ACID ON MORTALITY RATE IN
TRAUMA PATIENTS COMPARED TO TRAUMA PATIENTS
WITH NO TRANEXAMIC ACID TREATMENT
by Bradley Earl Tolar
December 2016
Traumatic injury is the leading cause of death for many age groups.
Traumatic accidents caused over 130,000 deaths in the United States in 2014.
This DNP project studied the effects of Tranexamic acid on mortality rate in
trauma patients. After the completion of a needs assessment at a local level II
trauma center, a literature review was performed. The literature showed a
decrease in mortality rate when patients were administered Tranexamic acid
within 3 hours of injury with statistically significant statistics. Also, the data from
the literature showed no correlation between vascular occlusive events and
Tranexamic acid use in trauma patients. Second, a practice change proposal
was drafted including the statistics found in the literature review. This proposal
was presented to available trauma surgeons at a local level II trauma center in
south Mississippi. Last, the trauma surgeons were asked to fill out a brief survey
asking if they would be willing to change their practice based off the information
provided. The surgeons were not willing to change their practice, but their
practice was currently up to date with the recommendations included in the
practice change proposal. Due to the project spanning over 2 years in time, the
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previously performed needs assessment was outdated by the completion of the
project.

iii

ACKNOWLEDGMENTS
I would like to offer a special thanks to Dr. Marjorie Everson, my
committee chair, for her help, support, and encouragement throughout the
process of this capstone project. Also, thank you Dr. Janie Butts and Dr. Melanie
Gilmore for your guidance and support throughout this process.

iv

TABLE OF CONTENTS
ABSTRACT ...........................................................................................................ii
ACKNOWLEDGMENTS .......................................................................................iv
LIST OF ABBREVIATIONS ................................................................................. vii
CHAPTER I – INTRODUCTION ........................................................................... 1
Clinical Problem Statement ........................................................................... 1
Needs Assessment ....................................................................................... 1
PICOT question ............................................................................................. 2
Significance of the Project ............................................................................. 2
Theoretical Framework .................................................................................. 3
CHAPTER II – REVIEW OF LITERATURE .......................................................... 5
Anatomy and Physiology of the Trauma Patient ............................................ 6
Clotting Cascade and Hemostasis ................................................................ 7
Hypercoagulable states ............................................................................. 8
Hypocoagulable state ................................................................................ 9
Drugs that Affect Coagulation........................................................................ 9
Tranexamic Acid.......................................................................................... 11
Studies ........................................................................................................ 12
CRASH-2 trial .......................................................................................... 12
Timing of Administration. ...................................................................... 13
v

Dosing of Administration. ..................................................................... 14
Adverse Outcomes of Tranexamic Acid? ............................................. 15
Cost Effectiveness................................................................................ 16
MATTERS trial ......................................................................................... 16
CHAPTER III – METHODS ................................................................................ 18
CHAPTER IV – DISCUSSION ............................................................................ 20
Further Research ........................................................................................ 21
DNP Essentials ........................................................................................... 21
CHAPTER V – SUMMARY ................................................................................. 23
APPENDIX A – Long Consent Form................................................................... 25
APPENDIX B – Clinical Evaluation Piece ........................................................... 27
APPENDIX C – Practice Change Proposal ........................................................ 28
APPENDIX D – Signed Support Leter ................................................................ 31
APPENDIX E - IRB Approval Letter .................................................................... 32
REFERENCES ................................................................................................... 33

vi

LIST OF ABBREVIATIONS
AACN

American Association of Colleges of Nursing

CDC

Centers for Disease Control

CRASH-2

Clinical Randomisation of an Antifibrinolytic in
Significant Hemorrhage-2

DNP

Doctorate of Nursing Practice

IRB

Institutional Review Board

MATTERS

Military Application of Tranexamic acid in Trauma
Emergency Resuscitation

tPA

Tissue Plasminogen Activator

USM

The University of Southern Mississippi

vii

CHAPTER I – INTRODUCTION
Clinical Problem Statement
Traumatic injuries are unplanned, life altering events that can affect a
family with no warning. Traumatic events are leading causes of mortality in many
different age groups, especially young people (CDC, 2014). While comorbidities
such as heart disease, respiratory disease, stroke, and cancer are responsible
for the deaths of many older individuals, trauma accidents still claim the lives of
many older individuals too (CDC, 2014). In a 2014 survey, the Centers for
Disease Control found that traumatic accidents (or unintentional injuries) were
the leading cause of death for people age 1 through age 44 in the United States
(CDC, 2014). The goals of this DNP project were to find evidence of Tranexamic
acid administration reducing mortality rate in trauma patients, and to present a
practice change proposal to local trauma surgeons.
Needs Assessment
Upon choosing the trauma patient population to study for the DNP project,
a needs assessment was completed at a local level II trauma center. At that time
in April 2014, the use of Tranexamic acid in the trauma patient population was
inconsistent at best. One of the trauma surgeons was an advocate for its use,
two of the trauma surgeons did not ever use the drug, and the other three
surgeons used it on occasion. With all available literature and statistics showing
better patient outcomes, the project was started as a practice change proposal.
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PICOT question
How does the administration of Tranexamic acid affect mortality rate in
trauma patients compared to trauma patients receiving no Tranexamic acid or
placebo? The patient population is acute trauma patients over the age of 16
being admitted to a nearby hospital for surgical intervention to minimize blood
loss. The intervention is administration of Tranexamic acid in the preoperative,
intraoperative, and postoperative phases of care. The control group will be the
group of patients who do not receive Tranexamic acid or who receive placebo
treatment (depending on the trial in which they were in). The outcome measured
will be mortality rate of patients for treatment versus control groups. The
timeframe the variable will be measured in will differ between the trials, but they
will all be within the first 30 days after surgery.
Significance of the Project
The main goal of this DNP project was to expand the use of Tranexamic
acid among trauma surgeons at a local level II trauma center. This was achieved
by submitting a practice change proposal to the trauma surgeons with the results
of the literature review included. The trauma patient population was studied in
the available literature in an effort to see if Tranexamic acid decreases mortality
rate as compared to a control group not receiving Tranexamic acid or receiving a
placebo treatment.
Traumatic accidents are leading causes of death in many age groups
(CDC, 2014). The reason for death from trauma is due to severe hemorrhage
limiting the oxygen carrying capacity of the blood and oxygen delivery to the
2

tissues. Tranexamic acid is an antifibrinolytic drug that works by impeding
fibrinolysis. Fibrinolysis is the body’s own way of breaking down blood clots to
make sure that the blood clots do not become problematic, such as those
causing stroke, pulmonary embolus, deep vein thrombus, or myocardial
infarction. By impeding fibrinolysis, the body would not break down clots, but
would further strengthen the clots that form. This may lead to less hemorrhage
and more stable trauma patients by maintaining adequate hemoglobin and
hematocrit concentrations in the body.
Theoretical Framework
The nursing theory chosen to guide the research is Roy’s adaptation
model. “According to this model, problems in adaptation materialize when the
adaptive systems of a person are unable to respond to stimuli from internal or
external environments” (Butts & Rich, 2015, p. 410). This statement mimics the
problems affecting the trauma patient in that the patient is unable to respond to
other stimuli to survive. The major elements involved in Roy’s adaptation model
are adaptation, person, environment, health, and goal of nursing (Roy, 2009).
The drug chosen, Tranexamic acid, will ultimately help with adaptation of the
patient to the stressful traumatic injury. The environment would include the
traumatic accident that the patient suffered as well as the stress of the surgery
that the patient is enduring. Also, the environment of the hospital and the
postoperative care unit that the patient is assigned to will affect the patient. The
health of the patient would be compromised, but Tranexamic acid has been
shown to improve the health in terms of mortality rate. The last major element of
3

Roy’s adaptation model is goal of nursing. The goal of nursing through this
project will be to improve trauma patient outcomes by expanding the use of
Tranexamic acid among local trauma surgeons at a local level II trauma center.
The fit between the DNP project and Roy’s adaptation model are near
perfect. Roy’s adaptation model states that there is never a perfect homeostatic
state but that body systems adapt to try and meet a given need depending of the
situation (Roy, 2009). In the project’s population, the body’s homeostasis is lost
by a traumatic injury which causes great risk for significant hemorrhage. The
cardiovascular stability is at risk and the body tries to adapt by causing a
tachycardia to combat the hypotension associated with the hemorrhage.
Tranexamic acid will look to help the homeostatic mechanisms that sometimes
fail with excessive blood loss.
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CHAPTER II – REVIEW OF LITERATURE
Tranexamic acid is a drug that is relatively new to the trauma patient
population. Tranexamic acid is currently used with great success in patient
populations at risk for excessive bleeding including: cardiac surgical patients,
obstetric/gynecologic patients with heavy menstrual cycles, and orthopedic
surgical patients. Some side effects that have been potentially linked to
Tranexamic acid include: stroke, deep vein thrombosis and pulmonary embolus.
Tranexamic acid has been used in trauma patients and during trauma surgeries,
but many physicians have not incorporated this drug into their practice, as
discovered from a needs assessment performed at a local level II trauma center.
Also, there are no published clinical guidelines available for Tranexamic acid in
the trauma patient population. The purpose of this literature review will be to
provide a risk-benefit analysis of Tranexamic acid in relation to the treatment of
trauma surgical patients. The topic of discussion will be centered around the
effect Tranexamic acid has on mortality rate in the trauma patient population as
compared to trauma patients that do not receive this treatment. Other important
points that will be reviewed include the dosing of Tranexamic acid, the timing of
Tranexamic acid administration in relation to injury, and incidence of blood
transfusion in patients receiving treatment as compared to patients not receiving
Tranexamic acid treatment.
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Anatomy and Physiology of the Trauma Patient
Nagelhout and Plaus (2014) defined traumatic injury as “a result of an
external force that ultimately disrupts normal structure and function of the body.
In most situations, the initial cause of injury is not a result of genetics or
environmental exposure, but circumstance and misfortune” (Nagelhout & Plaus,
2014, p. 914). Nagelhout and Plaus (2014) further state that traumatic injury is
the leading cause of death for people under 40 years of age. Hoffman added to
this point by stating that trauma can cause excessive bleeding by disruption of
blood vessels and that more than one-third of trauma patients will die of
exsanguination (Hoffman, 2004). This capstone project seeks to improve patient
outcomes in trauma patients.
Trauma patients often present to the hospital with multiple injuries, some
of which are not apparent upon initial physical assessment (Gruen et al., 2012).
Patients can have spleen or liver lacerations that are not diagnosed until the
patient has had adequate imaging scans to confirm internal bleeding. The
patient can sustain closed head injuries with subdural or epidural hematomas,
which lead to altered mental status and increased intracranial pressure. Also,
numerous types of orthopedic injuries are possible in trauma patients (Barash,
Cullen, Stoelting, Cahalan, & Stock, 2009). All of these injuries can possibly lead
the patient to excessive blood loss. This can cause a state of hypovolemia
leading to hypotension rather quickly (Gruen et al., 2012). Hypovolemia must be
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treated aggressively to restore the circulating volume in order to perfuse all vital
organs (Butterworth, Mackey, & Wasnick, 2013).
Often times, the trauma patient will require blood transfusion to maintain
an adequate hemoglobin and hematocrit (Gruen et al., 2012). Hemoglobin is
responsible for carrying oxygen from the lungs while the blood transports this
oxygen to the tissues for extraction. If the concentration of hemoglobin falls too
low, the tissues will not receive adequate oxygenation, even if the volume status
is adequate. It is necessary to keep an even balance of not only the volume
status, but also enough hemoglobin in the circulating blood to transport oxygen to
the tissues (Guyton & Hall, 2006).
Clotting Cascade and Hemostasis
To understand how Tranexamic acid works, one must first have a basic
understanding of the clotting cascade and hemostasis. Hemostasis simply
defined is reduction or prevention of blood loss. This is initially caused by local
vasoconstriction at the site of vascular trauma. The vasoconstriction is caused
by the platelet’s release of thromboxane A2, which is a potent vasoconstrictor.
Upon vascular injury, this vasoconstriction occurs to limit the amount of blood
loss while a platelet plug is formed to close the site of blood loss (Guyton & Hall,
2006).
The clotting cascade is a very complicated process consisting of more
than 50 substances. Clotting takes place in three essential steps. First, a
complex cascade of chemical reactions involving 12 or more coagulation factors
7

occurs in response to a vascular injury, and leaves an end product known as a
prothrombin activator. Second, this product helps in the conversion of
prothrombin to thrombin. Last, this helps turn fibrinogen into fibrin, which
ultimately forms a clot. The initial clot starts a positive feedback loop that
promotes more clotting (Guyton & Hall, 2006).
After the clot has slowed or stopped bleeding, fibrinolysis begins to occur.
Fibrinolysis breaks down the clot so it does not become pathologic and cause a
deep vein thrombus or pulmonary embolus. The plasma contains plasminogen
that is converted to plasmin when activated. Plasmin’s main job is to digest fibrin
fibers and some other procoagulants. Therefore, when plasmin is formed, it will
cause the clot to be broken down so it does not become pathologic (Guyton &
Hall, 2006).
As previously discussed, there are over 50 substances that contribute to
the clotting of blood. Some of these substances are procoagulants, leading the
body to cause clots. Some of these substances are called anticoagulants,
leading the blood to be thinner and less prone to clot (Guyton & Hall, 2006).
Hypercoagulable states
A hypercoagulable state is one in which there is an abundance of
procoagulant factors. A hypercoagulable state is considered positive when there
has been some type of vascular injury, such as with a trauma patient. This
hypercoagulable state is partially responsible for forming the fibrin clot that
eventually leads to cessation of blood loss. Hypercoagulable states other than
8

with vascular injury are usually unwanted and can lead to pathologic clots such
as deep vein thrombus, pulmonary embolus, stroke, or myocardial infarction
(Guyton & Hall, 2006). These 4 disease states can be caused by blood clots that
block the normal flow of blood and eventually cause hypoxia to the tissues distal
to the site of the clot.
Hypocoagulable state
A hypocoagulable state is one in which there is an abundance of
anticoagulant factors (Guyton & Hall, 2006). In the presence of vascular injury,
this could lead to excessive blood loss. However, there are many medical
conditions that necessitate patients to remain in a pharmacologically induced
hypocoagulable state (Guyton & Hall, 2006). Some of these include: history of
cardiac dysrhythmias, stroke, deep vein thrombus, pulmonary embolus, and
coronary artery disease. Most of these disease processes are caused from a
previous hypercoagulable state which caused the patient to suffer some type of
injury (Guyton & Hall, 2006). In turn, they are prescribed medications that work
to inhibit different specific parts of the clotting cascade to induce a
hypocoagulable state. This will help reduce the unwanted effects of pulmonary
embolus, deep vein thrombus, stroke, and heart attack.
Drugs that Affect Coagulation
To cause a hypocoagulable state, a drug must inhibit a certain step in the
clotting cascade. There are many classifications of these drugs based on what
step in the clotting cascade they effect. One category of drugs, called
9

anticoagulants, work to thin the blood by inhibiting a particular step of the clotting
cascade. Anticoagulants include: heparin, low-molecular-weight heparin,
Coumadin, and direct thrombin inhibitors such as Argatroban and Pradaxa
(dabigatran). There are also antiplatelet drugs that work to cause a
hypocoagulable state. These drugs work directly on the circulating platelets to
cause them not to agglutinate as easily. Antiplatelet drugs include: nonsteroidal
anti-inflammatory drugs, Plavix (clopidigrel), and Ticlid (ticlodipine HCl). There
are also herbal drugs which are usually not taken for the specific effect of
hypocoagulation, but that also have that effect. This category of drugs is
important to be aware of as patients often do not know that their herbal
medications have side effects affecting coagulation. Herbal medications causing
hypocoagulation of the blood include garlic, ginger, ginkgo, and fish oil. The
herbal medication known as black cohosh can cause the blood to be
hypercoagulable. The main procoagulant medication is Vitamin K. This drug can
be used as the reversal agent for a patient with increased bleeding times due to
Coumadin. Vitamin K is necessary for the production of many clotting factors in
the body. Antifibrinolytics is another class of drugs that cause hypercoagulation.
These drugs do not make the blood clot quicker, but they do improve the strength
of the clot. Antifibrinolytics include Tranexamic acid and Aminocaproic acid
(Nagelhout & Plaus, 2014).
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Tranexamic Acid
Tranexamic acid was the drug reviewed for this DNP project. Tranexamic
acid is an antifibrinolytic drug. As previously discussed, fibrinolysis is the internal
process of breaking down the clot once it has slowed or stopped bleeding.
Fibrinolysis is part of a system of checks and balances making sure hemostasis
is well regulated. After a clot has formed, blood flow is increased to the area and
thromboxane A2 and adenosine diphosphate (two potent vasoconstrictors) are
washed away to allow for increased flow of blood. This increase in blood flow
allows the body’s own tissue plasminogen activator (tPA) and urokinase to arrive
at the area with the intact clot. The body’s tPA and urokinase are catalysts in
converting plasminogen (already located in the clot) into plasmin. The plasmin is
then able to degrade the fibrin into fibrin degradation products and the clot is then
digested (Nagelhout & Plaus, 2014). Tranexamic acid works to prevent
fibrinolysis from occurring. Its chief mechanism of action is to block the
conversion of plasminogen to plasmin. With no active plasmin, the fibrin clot is
not broken down (Hensley, Martin, & Gravlee, 2013). The goal in trauma
patients is to stop the blood loss from occurring so that perfusion can be
maintained to the vital organs. By stopping the premature breakdown of fibrin
clots, trauma patients will have more adequate clotting to reduce blood loss and
maintain function of vital organs (Gruen et al., 2012).
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Studies
When searching the available literature for Tranexamic acid’s use in
trauma patients, two studies were a recurring reference in almost all articles.
The first of these studies, Clinical Randomisation of an Antifibrinolytic in
Significant Hemorrhage-2 (CRASH-2) trial, was conducted in 2010. The second
study, the Military Application of Tranexamic Acid in Trauma Emergency
Resusciation (MATTERS) trial, was conducted in 2012. Most articles found on
the selected population cited one or both of these two studies and looked at them
in different ways. While the MATTERS trial looked specifically at military
administration of Tranexamic acid and CRASH-2 trial looked at civilian
administration of the drug, both trials have data that is applicable to this project.
CRASH-2 trial
The CRASH-2 trial was conducted in 2010, and although it is greater than
5 years old, it is considered a gold standard in this patient population. Nearly all
articles cite this trial and/or MATTERS trial in their reviews. CRASH-2 trial
investigators studied the effects of Tranexamic acid on a total of 20,211 patients
across 40 countries and 274 hospitals. CRASH-2 trial includes civilian patients
suffering from traumatic injuries presenting with significant hemorrhages, as
evidenced by tachycardia and hypotension (Guerriero et al., 2011).
In the CRASH-2 trial, 10,060 patients were given Tranexamic acid as a
treatment following their traumatic accident, while 10,151 patients were given
placebos. Of the 20,211 total patients in this study, 1,063 patients died from
12

hemorrhage. Of these 1,063 mortalities, 489 were from the Tranexamic acid
treatment group, while 574 were from the control group that received placebos.
When comparing mortality of treatment group versus control group, 4.9 percent
of the treatment group died from hemorrhage and 5.7 percent of the control
group died from hemorrhage. Relative risk statistics show a 15% decrease in risk
of mortality due to hemorrhage when receiving Tranexamic acid when compared
to patients in control group (RR 0.85, CI 0.76 to 0.96; P = 0.0077) (Perel, Ker,
Morales Uribe, & Roberts, 2013). “These figures suggest that administration of
Tranexamic acid can reduce the risk of death from bleeding” (Livingstone, 2013,
p. 25). “The pooled data showed that antifibrinolytic drugs reduce the risk of
death from any cause by 10% (RR 0.90, 95% CI 0.85 to 0.97; P = 0.003). This
estimate is based primarily on data from the CRASH-2 trial of Tranexamic acid,
which contributed 99% of the data” (Ker, Roberts, Shakur, & Coats, 2015, p. 2).
Timing of Administration. According to Livingstone (2013), patients in the
CRASH-2 trial were placed into 1 of 3 groups in relation to timing of initial dose of
Tranexamic acid: within 1 hour of injury, between 1 and 3 hours of injury, longer
than 3 hours after injury. The data concluded that patients had a greater chance
of survival when administration of Tranexamic acid was within 1 hour after injury,
or between 1 and 3 hours after injury. When timing of administration was longer
than 3 hours from time of injury, mortality rate increased (RR 1.44, 95% CI 1.12
to 1.84; P = 0.004) (Livingstone, 2013).
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Researchers compared Tranexamic acid’s use in trauma patients to tissue
Plasminogen Activator (t-PA) use in ischemic stroke patients (Meurer, 2013).
When Tranexamic acid is given within 3 hours of injury the data shows promising
results of decreased mortality, but after 3 hours the results show more harm than
good. Meurer (2013) states that t-PA was shown to reduce the number of
patients with disabilities from stroke by 14 percent when given within 3 hours of
onset of symptoms. Nearly 20 years after this finding was confirmed with
research and a large trial, it is still not fully used in treatment facilities. Meurer
calls for Tranexamic acid to “become standard of care for trauma patients
worldwide long before the 20th anniversary of the CRASH-2 trial” (Meurer, 2013,
para. 8).
Guerriero, Cairns, Perel, Shakur, and Roberts (2011) found that early
treatment with Tranexamic acid is necessary to improve outcomes. They also
found that when Tranexamic acid is administered within 3 hours of injury, the risk
of death is reduced by 13 percent (RR 0.87, 95% CI 0.81 to 0.95). Guerriero et
al. (2011) claim that it can be harmful to administer Tranexamic acid outside of a
three hour window from the time of injury (Guerriero et al., 2011).
Dosing of Administration. Dosing of Tranexamic acid has been a question
across other patient populations. There was no variance in the dose of
Tranexamic acid in the CRASH-2 or MATTERS trials. Too large of a dose can
cause a hypercoagulable state that could lead to pulmonary emobolus, stroke, or
deep vein thrombus. Too small of a dose would not produce the therapeutic
14

effect of slowing down fibrinolysis. The only dose mentioned in regards to
trauma patients was referenced from the MATTERS trial. Livingstone (2013)
said the dose of Tranexamic acid in trauma patients was a 1 gram bolus given
over 10 minutes followed immediately by 1 gram given slowly over the next 8
hours (Livingstone, 2013). The initial bolus is given to load all of the receptors so
that fibrinolysis is slowed or stopped. The second dose is given slowly over 8
hours to keep a steady state of the active drug in circulation. With a half life of 3
hours, the active drug could be metabolized out of circulation before the need for
the drug is complete (Nagelhout & Plaus, 2014).
Adverse Outcomes of Tranexamic Acid? There are concerns surrounding
Tranexamic acid administration causing adverse vascular occlusive events,
especially in at risk patients. Patients with specific risks to these events are
those patients with a history of such events including: deep vein thrombus,
pulmonary embolus, myocardial infarction, and stroke. According to one
reviewer of the CRASH-2 trial “there is no evidence that antifibrinolytics have an
effect on the risk of vascular occlusive events (quality of evidence: Moderate)”
(Ker et al., 2015, p. 2).
There has also been much discussion as to whether Tranexamic acid has
any effect on the number of patients needing blood transfusion after traumatic
injury. Being that blood transfusion carries many risks, this is another topic of
interest among the possible benefits of Tranexamic acid administration.
According to the CRASH-2 trial “there is no evidence that antifibrinolytics have an
15

effect on the receipt of blood transfusion (quality of evidence: High)” (Ker et al.,
2015, p. 2).
Cost Effectiveness. According to Livingstone’s review of the CRASH-2
trial, Tranexamic acid is a much cheaper alternative to the numerous blood
products given to patients with traumatic hemorrhage. In the United Kingdom,
the four vials of Tranexamic acid needed to treat a patient was roughly 20 times
cheaper than one unit of packed red blood cells (Livingstone, 2013). Meurer
(2013) called Tranexamic acid “inexpensive” at less than 100 dollars and said it
was cheaper than the cost of starting an IV line and administering a liter of saline.
Guerriero et al. (2011) conducted a review with the single objective of studying
cost effectiveness. While their explanation of cost was much more in depth, it
still is considered a cost effective strategy. “Tranexamic acid is not only life
saving… but also that it is a highly cost effective intervention if administered
routinely to bleeding trauma patients in high, middle, and low income countries”
(Guerriero et al., 2011, p. 5).
MATTERS trial
The MATTERS trial is considered a gold standard of studies among
trauma patients receiving Tranexamic acid. The MATTERS trial was conducted
in 2012 and is a retrospective study that examined medical records of military
trauma patients over a 24-month period. In total, there were 896 patients with
combat-related injuries. The study included all patients who suffered from
combat injuries and had to receive at least one unit of packed red blood cells
16

within 24 hours of admission to the treatment facility. Many of these patients
received greater than 10 units of blood products and were categorized as
receiving a massive transfusion.
Two hundred ninety three of the 896 total patients received Tranexamic
acid while 603 did not receive Tranexamic acid. Roughly 50 percent of patients
receiving Tranexamic acid died within 30 days of receiving treatment. Sixty four
percent of patients not receiving Tranexamic acid died in the same time frame
(Livingstone, 2013).
Three hundred twenty one of the 896 total patients received mass
transfusion. One hundred twenty five of these 321 patients received Tranexamic
acid while 196 did not receive Tranexamic acid. Forty three percent of patients
receiving a mass transfusion and Tranexamic acid died within 30 days of
admission to hospital; compared with 64 percent of patients receiving a mass
transfusion and no Tranexamic acid treatment (Livingstone, 2013).
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CHAPTER III – METHODS
For this DNP project, a needs assessment was completed at a local level
II trauma center at the start of the project in early 2014. Following the needs
assessment, a review of the literature regarding the effects of Tranexamic acid
on mortality rate in trauma patients was conducted. A comprehensive literature
search was conducted to find relevant articles related to trauma patients
receiving Tranexamic acid as a treatment for preventing hemorrhage. Multiple
electronic databases were used during this search, but the majority of articles
were found in CINAHL, MEDLINE, and PubMed. The terms Tranexamic acid,
trauma, txa, antifibrinolytic, and hemorrhage were all used singly and in
combination. Many articles were duplicated in searches across other databases.
All articles found on this topic cited one of two trials that have taken place in this
population: the MATTERS trial or the CRASH-2 trial. Inclusion criteria for all
databases included articles written in the English language, full text articles only,
publication dates between 2010 and present time, patients were victims of a
traumatic injury, ages of patients were determined by the individual trials in which
they were in. Exclusion criteria included studies not published in the English
language, studies that did not include full text, studies conducted prior to 2010,
and patients in any other category besides trauma.
Data was gathered from other studies, namely the MATTERS trial and the
CRASH-2 trial, that have been previously completed. The most important data
collected was the effect of Tranexamic acid on mortality. There was also
18

research performed on dose of administration and timing of administration in
relation to injury.
Following the literature review, a practice change proposal to trauma
surgeons at a local level II trauma center was developed. The practice change
proposal was compiled using evidence from the literature on how to successfully
use Tranexamic acid in the trauma patient population to maximize the drug’s
potential and decrease the mortality rate of trauma patients. This proposal also
stated whether or not the use of Tranexamic acid is found to increase or
decrease the amount of blood products needed postoperatively.
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CHAPTER IV – DISCUSSION
After completing the review of literature and successfully completing
Institutional Review Board (IRB) at The University of Southern Mississippi (USM),
a practice change proposal was drafted and presented to available trauma
surgeons at a level II trauma center in south Mississippi. After presentation of
the proposal, a brief survey was administered to assess surgeons’ willingness to
change practice.
There was a total of 5 trauma surgeons currently practicing at the trauma
center. An individual attempt was made to schedule a meeting time with all 5 of
the surgeons for presentation of the findings and practice change proposal. Two
of the 4 surgeons were unavailable or uninterested. A response was never
obtained from 1 surgeon. Ultimately, two surgeons were presented the findings
and practice change proposal.
After obtaining consent from both participants, the findings of the literature
review were covered along with statistical evidence. The findings included
statistics of Tranexamic acid’s effect on mortality rate, incidence of vascular
occlusive events, incidence of blood transfusion, and cost effectiveness. Next, a
brief survey was administered that asked if the participant would consider a
practice change based on the information presented. Both participants answered
no to this question. Since initial meeting with these surgeons over two years
ago, much effort has been made to improve their use of the drug through
research of their own. This group of surgeons has access to literature that was
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not available through USM libraries database. Their use of Tranexamic acid in
trauma patients in on par with the recommendations made based off the
literature review.
Further Research
This project could be expanded upon in the future in the form of a
retrospective chart review on trauma patients that have received Tranexamic
acid to examine its effects on mortality rate in the local hospital. Also, further
research with more equipped databases could assess the effect of Tranexamic
acid on patients with a history of vascular occlusive events. One topic that was
never debated in the literature was the dose of Tranexamic acid. It was a set
dose of 1000 mg IV bolus followed by 1000 mg IV slowly over the next 8 hours.
All other variables were debated but this was not and the dose of administration
could be studied for further research.
DNP Essentials
The DNP essentials covered in this DNP project include numbers III, IV,
VI. Essential III is clinical scholarship and analytical methods for evidence-based
practice (American Association of Colleges of Nursing [AACN], 2006). This
essential was met through completion of the literature review and analyzing the
associated statistics. Essential IV is information systems/technology and patient
care technology for the improvement and transformation of health care (AACN,
2006). This essential was met using the literature databases to search for
literature related to the project. Essential VI is interprofessional collaboration for
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improving patient and population health outcomes (AACN, 2006). This essential
was met through collaboration with trauma surgeons to provide the highest level
of quality care for trauma patients.
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CHAPTER V – SUMMARY
The purpose of this capstone project was to evaluate the effects of
Tranexamic acid on mortality rate in the trauma patient population and to draft a
practice change proposal for local trauma surgeons. The primary outcome
studied was mortality rate of trauma patients receiving Tranexamic acid, while
also studying the effects on vascular occlusive events and incidence of blood
transfusions. A review of the literature was performed and the results of
previously performed trials were analyzed. Next, a practice change proposal was
drafted and presented to available surgeons at a level II trauma center in south
Mississippi. A survey was presented to the surgeons after presentation of the
practice change proposal. Due to their recent overhaul of their Tranexamic acid
protocol for trauma patients, none of the surgeons surveyed were willing to
consider a practice change.
The review of literature found that mortality rate was decreased in trauma
patients receiving Tranexamic acid and that it was statistically significant. The
literature also showed no difference in vascular occlusive events for trauma
patients receiving Tranexamic acid versus trauma patients with no Tranexamic
acid treatment.
The literature showed a decrease in mortality rate when trauma patients
are treated with Tranexamic acid. That was one of the goals of this study. While
the practice change proposal did not encourage trauma surgeons to change their
practice, the trauma patients in this area are receiving treatment with Tranexamic
23

acid that is up to date with current literature. The data and literature available to
the trauma surgeons was superior to the literature available to the author. Due to
the availability of the literature, the trauma patients in this area have a better
chance of survival due to the use of Tranexamic acid in the local level II trauma
center.
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APPENDIX A – Long Consent Form
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APPENDIX B – Clinical Evaluation Piece

Brad Tolar
Clinical Evaluation Piece for Capstone Project

1. Would you consider a practice change based on this information
presented today? YES or NO

2. If the answer is yes, what practice change would you implement?

27

APPENDIX C – Practice Change Proposal

CAPSTONE PROJECT FINDINGS & PRACTICE CHANGE PROPOSAL





Trauma is the leading cause of death for ages 1-44 (CDC, 2014)
o 3rd leading cause of death for ages 45-64 (CDC, 2014)
Tranexamic acid is an antifibrinolytic
o Impedes fibrinolysis: blocks conversion of plasminogen to plasmin
(plasmin normally breaks down clots)
o Does not lead to more clots forming, only strengthens pre-existing
clots
CRASH-2 trial (Clinical Randomisation of an Antifibrinolytic in Significant
Hemorrhage-2 trial), 2010
o 20,211 civilian patients
 10,060 were given Tranexamic acid as treatment
 10,151 were given placebos as treatment
o 1,063 deaths from hemorrhage
 489 of these deaths were administered Tranexamic acid; this
is 4.9% of the treatment group;
 547 of these deaths were administered placebo; this is 5.7%
of the control group
 Relative risk stats show a 15% decrease in risk of mortality
due to hemorrhage when receiving Tranexamic acid (RR
0.85, 95% CI 0.76 to 0.96) (Perel, Ker, Morales, & Roberts,
2013)
o Mortality rate from hemorrhage decreased by 15% (0.85, 95% CI
0.76 to 0.96; P = 0.0077) when compared to patients in control
group (Ker, Roberts, Shakur, & Coats, 2015)
o Treatment with Tranexamic acid within 1 hour of injury was
associated with a 32% decrease (RR 0.68, 95% CI 0.57 to 0.82; P
< 0.0001) in risk of death due to hemorrhage (Ker, Roberts, Shakur,
& Coats, 2015)
o Treatment with Tranexamic acid between 1 and 3 hours after injury
was associated with a 21% reduction (RR 0.79, 95% CI 0.64 to
0.97; P = 0.03) in risk of death due to hemorrhage (Ker, Roberts,
Shakur, & Coats, 2015)
o Mortality rate from hemorrhage increased when timing of
administration was greater than 3 hours after injury (Livingstone,
2013). Guerriero et al. (2011) also says timing of administration
must be within 3 hours of injury and data shows 44% increase in
risk of death due to hemorrhage when administration of Tranexamic
acid is more than 3 hours after injury (RR 1.44, 95% CI 1.12 to
1.84; P = 0.004) (Ker, Roberts, Shakur, & Coats, 2015)
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o Livingstone (2013) said CRASH-2 used a dose of 1 gram bolus
over 10 minutes, followed by 1 gram slowly infused over the next 8
hours
MATTERS trial (Military Application of Tranexamic acid in Trauma
Emergency Resuscitation trial), 2012
o 896 military patients
o 293 received Tranexamic acid treatment
 Roughly 50% died within 30 days of injury/treatment
(Livingstone, 2013)
o 603 did not receive Tranexamic acid treatment
 64% died within 30 days of injury and no treatment
(Livingstone, 2013)
o 321 received mass transfusion (greater than 10 units)
 125 received Tranexamic acid
 43% died within 30 days
 196 did not receive Tranexamic acid
 64% died within 30 days
Pooled data from both trials suggests that Tranexamic acid decreased risk
of death from any cause by 10% (RR 0.90, 95% CI 0.85 to 0.97; P =
0.003) (Ker, Roberts, Shakur, & Coats, 2015)
Adverse Outcomes??
o “There is no evidence that antifibrinolytics have an effect on the risk
of vascular occlusive events (quality of evidence: Moderate)” (Ker,
Roberts, Shakur, & Coats, p. 2, 2015)
 Vascular occlusion (RR 0.69, 95% CI 0.44 to 1.07; P =
0.096)
 Stroke (RR 1.60, 95% CI 0.52 to 4.89; P= 0.40
 Pulmonary Embolism (RR 0.86, 95% CI 0.46 to 1.61; P =
0.63)
o “There is no evidence that antifibrinolytics have an effect on the
receipt of blood transfusion (RR 0.98, 95% CI 0.96 to 1.01; P =
0.21) (quality of evidence: High)” (Ker, Roberts, Shakur, & Coats, p.
2, 2015)
Cost Effectiveness
o Livingstone (2013) said in the United Kingdom, the Tranexamic
acid treatment was 20 times cheaper than one unit of PRBCs
o Cost of Tranexamic acid for FGH is $24.47 per 1 gram dose

PROPOSAL


More widespread use of Tranexamic acid in trauma patients (age 16 and
over) with risk of significant bleeding
o This does not apply to patients with traumatic brain injury with no
other injuries
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1st dose must be given within 3 hours of injury. Times longer than 3 hours
are associated with increased risk of death
Dose used in literature was 1 gram IV loading dose over 10 minutes
followed by 1 gram IV given slowly over the next 8 hours
o Dose was not researched in the literature, but this seemed to be
standardized among trials

Further Research?




Dosing of administration, as this seems to not be debated anywhere for
trauma patients
Outcomes on patients with history of vascular occlusive events
Statistical analysis among trauma patients at FGH (cost-prohibitive for me)

30

APPENDIX D – Signed Support Leter
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APPENDIX E - IRB Approval Letter
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